文献速递白血病

二代测序检测的克隆性基因突变对接受强化巩固治疗的RUNX1-RUNX1T1阳性急性髓系白血病患者的预后价值

[The prognostic value of cloned genetic mutations detected by second-generation sequencing in RUNX1-RUNX1T1 positive acute myeloid leukemia patients receiving intensive consolidation therapy].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该研究回顾性分析2011年7月至2017年8月在苏州大学附属第一医院CR1状态下接受强化巩固治疗的79例RUNX1-RUNX1T1阳性AML患者,采用Kaplan-Meier曲线和Cox回归模型分析初诊白细胞计数及基因突变对OS和DFS的影响。结果显示初诊白细胞计数越高OS越短(P=0.030),C-KIT exon17突变患者OS(P=0.010)和DFS(P=0.006)明显缩短,FLT3-ITD突变患者OS缩短(P=0.048)、DFS缩短(P=0.071),多因素分析显示C-KIT exon17和FLT3-ITD突变均为影响预后的独立因素。

要点

  • 79例中C-KIT突变25例(31.6%),其中exon17突变19例(24.1%)、exon8突变5例(6.3%)。
  • C-KIT exon17突变患者OS(P=0.010)和DFS(P=0.006)明显缩短。
  • FLT3-ITD突变患者OS缩短(P=0.048),DFS缩短(P=0.071)。

核心结论

  • 在接受强化巩固治疗的RUNX1-RUNX1T1阳性AML患者中,初诊白细胞计数高、C-KIT exon17突变和FLT3-ITD基因突变提示预后较差,有助于细化危险度分层、个体化治疗和评估预后。

研究设计与样本

  • 回顾性分析2011年7月至2017年8月在苏州大学附属第一医院CR1状态下接受高剂量化疗或自体造血干细胞移植(强化巩固治疗)的79例RUNX1-RUNX1T1阳性AML患者。
  • 采用Kaplan-Meier曲线和Cox回归模型分析初诊白细胞计数及基因突变对OS和DFS的影响。

主要发现

  • 79例中检出C-KIT、FLT3、CEBPA、DNMT3A基因突变者分别为25例(31.6%)、6例(7.6%)、8例(8.9%)、1例(1.3%)。
  • C-KIT exon17及C-KIT exon8突变分别为19例(24.1%)、5例(6.3%),FLT3-ITD突变为5例(6.3%)。
  • 初诊白细胞计数越高,患者OS时间越短(P=0.030)。
  • 合并C-KIT exon17突变患者OS时间(P=0.010)和DFS时间(P=0.006)明显缩短。
  • 合并FLT3-ITD基因突变患者OS时间缩短(P=0.048),DFS时间缩短(P=0.071)。

关键数值与推荐

  • 多因素分析显示合并C-KIT exon17和FLT3-ITD突变均为影响患者预后的独立因素。

临床怎么用

  • 原文结论认为初诊白细胞计数、C-KIT exon17突变和FLT3-ITD突变提示预后较差,对细化危险度分层、个体化治疗和评估预后有指导意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the prognostic value of clonal gene mutations detected by second-generation sequencing in patients with positive RUNX1-RUNX1T1 acute myeloid leukemia (AML) who received high-dose chemotherapy or autologous transplantation (intensive consolidation therapy) in the first complete remission (CR(1)) state. Methods: 79 AML patients with positive RUNX1-RUNX1T1 who received intensive consolidation therapy in CR(1) state from July 2011 to August 2017 were analyzed retrospectively. Kaplan-Meier curve and Cox regression model were used to figure out the effect of leukocyte counts at onset and gene mutations for prognosis. Results: C-KIT, FLT3, CEBPA and DNMT3A gene mutations were found in 25 (31.6%) , 6 (7.6%) , 7 (8.9%) and 1 (1.3%) patient among the population. Mutations in C-KIT exon17 and C-KIT exon8 were detected in 19 (24.1%) and 5 (6.3%) cases, respectively, and mutations of FLT3-ITD were confirmed in 5 (6.3%) cases. The higher leukocyte counts presented at onset of leukemia, the shorter overall survival (OS) was seen in these patients (P=0.03) . Patients with C-KIT exon17 mutation had significantly shorter OS (P=0.01) and disease free survival (DFS) (P=0.006) compared with those without gene mutations, and patients with FLT3-ITD gene mutation got the inferior OS (P=0.048) and DFS (P=0.071) . Conclusion: In AML patients with positive RUNX1-RUNX1T1 receiving intensive consolidation therapy, the white blood cell counts at onset of leukemia, C-KIT mutations in exon 17, and FLT3-ITD gene mutations suggest poor prognosis, which would contribute to elaborate risk stratification, personalized treatment and predict prognosis for these patients. 目的: 探讨基于二代测序检测技术下的克隆性基因突变对第1次完全缓解(CR(1))状态下接受高剂量化疗或自体造血干细胞移植(强化巩固治疗)的RUNX1-RUNX1T1融合基因阳性急性髓系白血病(AML)预后的影响。 方法: 收集2011年7月至2017年8月在苏州大学附属第一医院CR(1)状态下接受强化巩固治疗的79例RUNX1-RUNX1T1融合基因阳性AML患者的临床资料,通过Kaplan-Meier曲线、Cox回归模型分析临床因素及突变基因对患者总生存(OS)和无病生存(DFS)时间的影响。 结果: 在79例患者中,检出C-KIT、FLT3、CEBPA、DNMT3A基因突变者分别为25例(31.6%)、6例(7.6%)、8例(8.9%)、1例(1.3%),其中C-KIT exon17及C-KIT exon8突变分别为19例(24.1%)、5例(6.3%),FLT3-ITD突变为5例(6.3%)。初诊白细胞计数越高,患者的OS时间越短(P=0.030),合并C-KIT exon17突变患者的OS时间(P=0.010)和DFS时间(P=0.006)明显缩短,合并FLT3-ITD基因突变患者的OS时间(P=0.048)和DFS时间(P=0.071)缩短。多因素分析显示合并C-KIT exon17和FLT3-ITD突变均为影响患者预后的独立因素。 结论: 在接受强化巩固治疗的RUNX1-RUNX1T1融合基因阳性AML患者中,C-KIT exon 17、FLT3-ITD基因突变提示预后较差,这将对细化患者危险度分层、个体化治疗、评估预后有指导意义。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yu JQ, Xue SL, Li Z, et al. [The prognostic value of cloned genetic mutations detected by second-generation sequencing in RUNX1-RUNX1T1 positive acute myeloid leukemia patients receiving intensive consolidation therapy]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32311890. doi:10.3760/cma.j.issn.0253-2727.2020.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。